Treatment of tinea capitis by oral terbinafin and grisofulvin

Comparison of oral terbinafin and grisofulvin in the treatment of tinea capitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201704056403N8

Enrollment

Registered

2017-11-12

Start date

2017-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinea capitis. B35-B49

Interventions

In one group treatment with oral grisofulvin In other group treatment with oral terbinafin.

Treatment - Drugs

In one group treatment with oral grisofulvin In other group treatment with oral terbinafin

Eligibility

Sex/Gender

All

Age

2 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Tinea documented by laboratory assessment Exclusion criteria: Pregnancy: infancy, breastfeeding: sensitivity to terbinafin and grisofulvin: previous treatment with antifungal drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treatment of tinea capitis. Timepoint: The end of 2th week, 1th, 2th and 3th months. Method of measurement: clinical observation and laboratory assesment.	—

Secondary

Measure	Time frame
Recurrence. Timepoint: The end 1 week, 1th, 2th and 3th months. Method of measurement: Clinical observation and labratory assesmsnt.;Permanent hair loss. Timepoint: The end 1 week, 1th, 2th and 3th months. Method of measurement: Clinical observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contact?Dr Hossein Kavoussi

Kermanshah University of Medical Sciences

hkawosi@kums.ac.ir+98 83 3825 6643

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026